GlassScriptPhysician profile
Heather Oberneder
NPI 1487203733
$7,262.19
in general payments reported to CMS, 2019-2025
28 companies · $2,027 in 2025
The $2,027 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $554 · 2022: $1,108 · 2023: $1,329 · 2024: $2,244 · 2025: $2,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,401 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,401.39 |
| Education | $198.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,453.74 | 2021-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $821.98 | 2021-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $719.34 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $602.81 | 2021-2025 | |
| Ardelyx, INC. | $546.44 | 2023-2025 | Ibsrela |
| Amgen INC. | $437.10 | 2021-2025 | Krystexxa, Tavneos |
| Mallinckrodt Hospital Products INC. | $402.02 | 2021-2025 | Acthar, Terlivaz |
| Calliditas Therapeutics US INC. | $332.16 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $322.68 | 2021-2025 | Veltassa |
| Akebia Therapeutics INC | $272.04 | 2021-2025 | Vafseo, Auryxia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.46 | 2023-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $174.29 | 2022-2024 | Gattex |
| Opko Pharmaceuticals, LLC | $153.46 | 2022-2025 | Rayaldee |
| Aurinia Pharma U.S., INC. | $147.01 | 2021-2024 | Lupkynis |
| Fresenius USA Marketing, INC. | $145.83 | 2022-2025 | Velphoro, Velphoro |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $86.78 | 2025 | Ozempic |
| Ani Pharmaceuticals, INC. | $81.72 | 2023-2025 | Purified Cortrophin Gel |
| Scpharmaceuticals INC. | $64.61 | 2024-2025 | |
| Daiichi Sankyo INC. | $48.32 | 2023-2024 | Injectafer |
| Alexion Pharmaceuticals, INC. | $44.19 | 2022-2025 | Ultomiris |
| Renalytix Ai, INC. | $41.82 | 2023-2024 | Kidneyintelx Blood Collection Convenience Kit |
| Boston Scientific Corporation | $35.58 | 2021-2022 | |
| La Jolla Pharmaceutical Company | $18.65 | 2024 | Giapreza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.56 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $17.00 | 2025 | Benlysta |
| Shield Therapeutics INC | $15.77 | 2023 | Accrufer |
| Gilead Sciences, INC. | $15.66 | 2021 | |
| Horizon Therapeutics Plc | $14.17 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Oberneder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.